Xencor stock fell 4.96 percent as targets diverged

Published on 10/07/2026 at 05:52 | Editorial responsibility: Rafael Müller, Editor-in-Chief AD HOC NEWS

Xencor stock faces a USD 31.12 consensus target from 10 analysts as of September 26, 2026. Q2 revenue reached USD 51.22 million, up 17.4 percent year over year.

XNCR, US98401F1057, Illustration mit AI erstellt.

Xencor stock (ISIN US98401F1057) fell 4.96 percent to USD 24.36 on Nasdaq on October 6, 2026, placing the clinical-stage biotech at 79.6 percent of its 52-week range between USD 10.38 and USD 30.61. The move leaves the pipeline and the next earnings date as the key checkpoints for the valuation.

Analysts set a USD 31.12 target

According to MarketBeat on September 26, 2026, 10 firms gave Xencor a Moderate Buy consensus, with five Buy ratings, one Strong Buy, three Holds and one Sell. The average 12-month target was USD 31.12, while published targets ranged from USD 20 to USD 46.

The individual calls show a wide valuation spread. MarketBeat reported on September 30, 2026, that Wells Fargo began coverage with an Overweight rating and a USD 55 price target. That target stands 125.9 percent above the October 6 price, while the consensus target is 27.8 percent higher.

Q2 revenue rose 17.4 percent

Xencor generated USD 51.221 million in Q2 2026, according to the standardized financial statement for the quarter ended June 30, 2026. Net loss attributable to common shareholders was USD 21.729 million, and diluted GAAP loss per share was USD 0.29.

MarketBeat reported that adjusted loss per share of USD 0.29 beat the USD 0.80 consensus loss by USD 0.51, while revenue of USD 51.22 million exceeded the USD 18.89 million estimate. Revenue increased 17.4 percent from the comparable quarter, but the company remained unprofitable.

Nasdaq valuation follows the pipeline

Xencor develops engineered antibodies and cytokine therapeutics for cancer, autoimmune diseases and other serious conditions. Its XmAb platform gives the company a pipeline-driven valuation, which explains the gap between the USD 20 low target and Wells Fargo's USD 55 view.

Cash and cash equivalents stood at USD 44.663 million on June 30, 2026, while operating cash flow was negative USD 55.658 million in Q2 2026. For investors, the contrast between revenue growth and cash consumption is central to the next clinical and financial update.

Xencor stock stays below its yearly high

Xencor stock was last at USD 24.36 on Nasdaq on October 6, 2026 at 4:00 p.m. ET, with a market capitalization of USD 1.8 billion and volume of 1,245,797 shares.